Funding for this research was provided by:
Received: 21 December 2017
Accepted: 8 February 2018
First Online: 26 February 2018
Ethics approval and consent to participate
: This study was approved by the institutional review boards of Wakayama Medical University and each participating institution. All patients provided necessary consent to participate in this study.
: No individual personal data are included in the study. All patients provided necessary consent to participate in this study.
: Dr. Yamamura reports receipt of lecture fees from Hospira Japan, Nipro, and Asahi Kasei and educational consulting fees from Toray Industries, CSL Behring, Teijin Pharma, and Nihon Pharmaceutical. Dr. Kawazoe reports receipt of lecture fees from Hospira Japan and Pfizer Japan and a scholarship from Hospira Japan. Dr. Miyamoto reports receipt of lecture fees from Becton Dickinson and Pfizer Japan. Dr. Morimoto reports receipt of lecture fees from AbbVie, AstraZeneca, Daiichi-Sankyo, Kowa, Kyorin, Mitsubishi-Tanabe, and Pfizer Japan and consulting fees from Asahi Kasei and Boston Scientific. Dr. Tomonori Yamamoto and Dr.Yoshinori Ohta, have no competing interests. The other authors declare no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.